AC IMMUNE SA SF-02
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more
AC IMMUNE SA SF-02 (IMR) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AC IMMUNE SA SF-02 (IMR) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AC IMMUNE SA SF-02 - Net Assets Trend (None–None)
This chart illustrates how AC IMMUNE SA SF-02's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AC IMMUNE SA SF-02 (None–None)
The table below shows the annual net assets of AC IMMUNE SA SF-02 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AC IMMUNE SA SF-02's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AC IMMUNE SA SF-02 Competitors by Market Cap
The table below lists competitors of AC IMMUNE SA SF-02 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XRF Scientific Ltd
AU:XRF
|
$108.79 Million |
|
Kginicis Co.Ltd
KQ:035600
|
$108.80 Million |
|
Unitech Limited
NSE:UNITECH
|
$108.81 Million |
|
NXGCF
OTCQX:NXGCF
|
$108.83 Million |
|
Zimplats Holdings Limited
PINK:ZMPLF
|
$108.77 Million |
|
LH Financial Group Public Company Limited
BK:LHFG
|
$108.76 Million |
|
Hyundai Pharm
KO:004310
|
$108.67 Million |
|
Datalogic S.p.A
OTCGREY:DLGCF
|
$108.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AC IMMUNE SA SF-02's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AC IMMUNE SA SF-02's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AC IMMUNE SA SF-02 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AC IMMUNE SA SF-02's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AC IMMUNE SA SF-02 (IMR) | €- | N/A | N/A | $108.78 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |